Galapagos NV
-1.54% €26.92
17:30 – 19/09/2024Nieuws van Galapagos NV
Belgium stocks higher at close of trade; BEL 20 up 0.33%
Bron: Yahoo Entertainment
Autheur: Investing.com
Gepubliceerd op: 2024-08-22
Investing.com – Belgium stocks were higher after the close on Thursday, as gains in the Healthcare, Telecoms and Basic Materials sectors led shares higher.
Galapagos receives transparency notification from FMR LLC
Bron: GlobeNewswire
Autheur: Galapagos NV
Gepubliceerd op: 2024-08-20
Mechelen, Belgium; 20 August 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.
Galapagos receives transparency notification from EcoR1 Capital
Bron: GlobeNewswire
Autheur: Galapagos NV
Gepubliceerd op: 2024-09-16
Mechelen, Belgium; 16 September 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from EcoR1 Capital LLC.
Galapagos ontvangt transparantieverklaring van FMR LLC
Bron: GlobeNewswire
Autheur: Galapagos NV
Gepubliceerd op: 2024-08-20
Mechelen, België; 20 augustus 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van FMR LLC.
Galapagos ontvangt transparantieverklaring van EcoR1 Capital
Bron: GlobeNewswire
Autheur: Galapagos NV
Gepubliceerd op: 2024-09-16
Mechelen, België; 16 september 2024, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een kennisgeving van belangrijke deelneming ontvangen van EcoR1 Capital, LLC.
Galapagos NV (NASDAQ:GLPG) Shares Bought by Headlands Technologies LLC
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-18
Headlands Technologies LLC raised its holdings in Galapagos NV (NASDAQ:GLPG – Free Report) by 56.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,233…
Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Reduce” from Brokerages
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-15
Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) have received an average rating of “Reduce” from the five research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four hav…
Galapagos (NASDAQ:GLPG) Shares Gap Up to $24.89
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-08-26
Galapagos NV (NASDAQ:GLPG – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $24.89, but opened at $25.90. Galapagos shares last traded at $25.94, with a volume of 33,713 shares changing hands. Analyst Upgrade…
Galapagos (NASDAQ:GLPG) Trading Up 3.7%
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-08-29
Galapagos NV (NASDAQ:GLPG – Get Free Report)’s stock price was up 3.7% during trading on Tuesday . The stock traded as high as $29.54 and last traded at $29.43. Approximately 132,275 shares were traded during trading, an increase of 2% from the average daily …
Q3 2024 Earnings Forecast for Galapagos NV (NASDAQ:GLPG) Issued By Leerink Partnrs
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-12
Galapagos NV (NASDAQ:GLPG – Free Report) – Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for Galapagos in a note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipa…
Galapagos (NASDAQ:GLPG) Shares Pass Below 200-Day Moving Average of $30.03
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-08-20
Galapagos NV (NASDAQ:GLPG – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $30.03 and traded as low as $24.45. Galapagos shares last traded at $24.86, with a volume of 87,277 shar…
Galapagos kondigt FDA-goedkeuring aan van IND-aanvraag voor fase 1/2 ATALANTA-1 studie van CD19 CAR-T, GLPG5101, in recidief/refractair non-Hodgkin lymfoom
Bron: GlobeNewswire
Autheur: Galapagos NV
Gepubliceerd op: 2024-08-23
Mechelen, België; 23 augustus 2024, 07:00 CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat de U.S. Food and Drug Administration (FDA) Galapagos’ Investigational New Drug (IND)-aanvraag h…
Equities Analysts Issue Forecasts for Galapagos NV’s FY2024 Earnings (NASDAQ:GLPG)
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-11
Galapagos NV (NASDAQ:GLPG – Free Report) – Stock analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for Galapagos in a research note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the b…
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
Bron: GlobeNewswire
Autheur: Galapagos NV
Gepubliceerd op: 2024-08-23
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) applicati…
Major Investor Says Galapagos Is ‘Undervalued,’ Plans To Push On Company’s ‘Performance’ And ‘Strategic Opportunities’
Bron: Biztoc.com
Autheur: benzinga.com
Gepubliceerd op: 2024-08-26
Galapagos NV (NASDAQ:GLPG) stock is trading higher on Monday as Ecor1 Capital reported a 9.9% stake in the European biotech firm in a 13D filing. EcoR1 Capital is now planning to talk to the Belgian biotech about its performance, business, operations, strateg…
Petros Pharmaceuticals (NASDAQ:PTPI) versus Galapagos (NASDAQ:GLPG) Financial Contrast
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-06
Galapagos (NASDAQ:GLPG – Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividend…
Galapagos (NASDAQ:GLPG) Upgraded to “Hold” by Leerink Partnrs
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-10
Leerink Partnrs upgraded shares of Galapagos (NASDAQ:GLPG – Free Report) to a hold rating in a research report report published on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Galapagos’ Q4 2024 earnings at ($0.17) EPS, FY2024 …
Galapagos (NASDAQ:GLPG) Earns Market Perform Rating from Analysts at Leerink Partners
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-10
Leerink Partners initiated coverage on shares of Galapagos (NASDAQ:GLPG – Free Report) in a report released on Monday morning, Marketbeat reports. The brokerage issued a market perform rating and a $24.00 target price on the biotechnology company’s stock. Sep…
Belgium stocks lower at close of trade; BEL 20 down 0.32%
Bron: Investing.com
Autheur: Investing.com
Gepubliceerd op: 2024-09-18
Belgium stocks lower at close of trade; BEL 20 down 0.32%
Belgium stocks higher at close of trade; BEL 20 up 0.52%
Bron: Investing.com
Autheur: Investing.com
Gepubliceerd op: 2024-09-13
Belgium stocks higher at close of trade; BEL 20 up 0.52%
Comparing Adaptimmune Therapeutics (NASDAQ:ADAP) & Gilead Sciences (NASDAQ:GILD)
Bron: ETF Daily News
Autheur: MarketBeat News
Gepubliceerd op: 2024-09-11
Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutio…
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Bron: The BMJ
Autheur: Burmester, G. R., Gottenberg, J.-E., Caporali, R., Winthrop, K. L., Tanaka, Y., Ekoka Omoruyi, E. V., Rajendran, V., Van Hoek, P., Van Beneden, K., Takeuchi, T., Westhovens, R., Aletaha, D.
Gepubliceerd op: 2024-08-27
Objectives To update the long-term safety profile of filgotinib, a Janus kinase-1 preferential inhibitor, in patients with moderate-to-severe rheumatoid arthritis. Methods Data from seven trials were integrated ([NCT01888874][1], [NCT01894516][2], [NCT028897…
Pagina’s
Social Media
AEX
- Shell PLC
- Nationale-Nederlanden
- Koninklijke Ahold Delhaize NV
- ASR Nederland NV
- Akzo Nobel NV
- AEGON N.V.
- Adyen NV
- Wolters Kluwer NV
- ArcelorMittal SA
- ASML Holding NV
- ABN Amro Bank NV
- DSM-Firmenich AG
- ING Groep NV
- Imcd NV
- RELX PLC
- Heineken N.V.
- Unilever plc
- Koninklijke Philips NV
- Prosus NV
- ASM International NV
- Koninklijke KPN N.V.
- Randstad NV
- BE Semiconductor Industries
- EXOR NV
- UMG
AMX
- Just Eat Takeaway.com NV
- Galapagos NV
- AALBERTS NV
- Advanced Metallurgical Group
- Air France-KLM
- Alfen N.V.
- ALLFUNDS GROUP
- Aperam
- Arcadis
- Basic-Fit
- Corbion
- CTP
- Eurocommercial Properties
- Fagron
- Flow Traders
- Fugro
- INPOST
- JDE PEET’S
- OCI
- SBM Offshore
- SIGNIFY NV
- TKH Group
- Van Lanschot Kempen NV
- Vopak Koninklijke
- WDP
AScX
- Accsys Technologies
- ACOMO
- Avantium
- AZERION
- BS Group SA
- BAM Groep Koninklijke
- Brunel International
- CM.COM
- EBUSCO HOLDING
- FASTNED
- ForFarmers
- Heijmans
- Kendrion
- Nedap N.V.
- NSI
- Pharming Group
- PostNL Koninklijke
- Sif Holding
- Sligro Food Group
- TomTom
- Vastned
- VIVORYON THERAPEUTICS N.V.
- Wereldhave
- Renewi plc
- Lucas Bols
Gemaakt door beleggers voor beleggers